Usefulness and limitations of comprehensive characterization of mRNA splicing profiles in the definition of the clinical relevance of BRCA1/2 variants of uncertain significance by Gelli, E. et al.
cancers
Article
Usefulness and Limitations of Comprehensive
Characterization of mRNA Splicing Profiles in the
Definition of the Clinical Relevance of BRCA1/2
Variants of Uncertain Significance
Elisa Gelli 1,†, Mara Colombo 2,† , Anna Maria Pinto 1,3 , Giovanna De Vecchi 2,
Claudia Foglia 2, Sara Amitrano 3, Valeria Morbidoni 4,5, Valentina Imperatore 1,
Siranoush Manoukian 6, Margherita Baldassarri 3, Caterina Lo Rizzo 3, Lorenza Catania 1,
Elisa Frullanti 1, Enrico Tagliafico 7, Laura Cortesi 8, Federica Spaggiari 8,
Maria Antonietta Mencarelli 3 , Eva Trevisson 4,5, Paolo Radice 2, Alessandra Renieri 1,3,*
and Francesca Ariani 1,3
1 Medical Genetics, University of Siena, 53100 Siena, Italy; elisa.gelli@student.unisi.it (E.G.);
annamaria.pinto@dbm.unisi.it (A.M.P.); va.imperatore@gmail.com (V.I.); catania4@student.unisi.it (L.C.);
elisa.frullanti@dbm.unisi.it (E.F.); francesca.ariani@unisi.it (F.A.)
2 Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS
Istituto Nazionale dei Tumori (INT), 20133 Milan, Italy; Mara.Colombo@istitutotumori.mi.it (M.C.);
giovanna.devecchi@cogentech.it (G.D.V.); Claudia.Foglia@istitutotumori.mi.it (C.F.);
Paolo.Radice@istitutotumori.mi.it (P.R.)
3 Genetica medica Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy;
sara.amitrano@dbm.unisi.it (S.A.); margherita.baldassarri@dbm.unisi.it (M.B.); lorizzo2@unisi.it (C.L.R.);
mariaantonietta.mencarelli@unisi.it (M.A.M.)
4 Department of Woman and Child Health, University of Padova, 35128 Padova, Italy;
valeria.morbidoni@gmail.com (V.M.); eva.trevisson@unipd.it (E.T.)
5 Istituto di Ricerca Pediatrica, IRP, Città della Speranza, 35129 Padova, Italy
6 Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto
Nazionale dei Tumori (INT), 20133 Milan, Italy; Siranoush.Manoukian@istitutotumori.mi.it
7 Department of Medical and Surgical Science, Center for Genome Research, University of Modena
and Reggio Emilia, 41125 Modena, Italy; enrico.tagliafico@unimore.it
8 Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria Policlinico,
University of Modena and Reggio Emilia, 41124 Modena, Italy; cortesi.laura@aou.mo.it (L.C.);
hbc@unimore.it (F.S.)
* Correspondence: alessandra.renieri@unisi.it; Tel.: +39-0577-233303; Fax: +39-0577-233325
† These authors equally contributed to the manuscript.
Received: 11 January 2019; Accepted: 20 February 2019; Published: 1 March 2019


Abstract: Highly penetrant variants of BRCA1/2 genes are involved in hereditary predisposition
to breast and ovarian cancer. The detection of pathogenic BRCA variants has a considerable
clinical impact, allowing appropriate cancer-risk management. However, a major drawback is
represented by the identification of variants of uncertain significance (VUS). Many VUS potentially
affect mRNA splicing, making transcript analysis an essential step for the definition of their
pathogenicity. Here, we characterize the impact on splicing of ten BRCA1/2 variants. Aberrant splicing
patterns were demonstrated for eight variants whose alternative transcripts were fully characterized.
Different events were observed, including exon skipping, intron retention, and usage of de novo and
cryptic splice sites. Transcripts with premature stop codons or in-frame loss of functionally important
residues were generated. Partial/complete splicing effect and quantitative contribution of different
isoforms were assessed, leading to variant classification according to Evidence-based Network for
the Interpretation of Mutant Alleles (ENIGMA) consortium guidelines. Two variants could be
classified as pathogenic and two as likely benign, while due to a partial splicing effect, six variants
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remained of uncertain significance. The association with an undefined tumor risk justifies caution
in recommending aggressive risk-reduction treatments, but prevents the possibility of receiving
personalized therapies with potential beneficial effect. This indicates the need for applying additional
approaches for the analysis of variants resistant to classification by gene transcript analyses.
Keywords: splicing; BRCA; mRNA analysis; VUS
1. Introduction
Breast cancer (BC) represents a priority public health problem, being the most common cancer
diagnosed in women worldwide and a leading cause of cancer deaths [1–3]. The most relevant
predisposing factor is family history. The risk increases with the number of affected relatives and
the age of cancer onset. Approximately 5–10% of BC cases are associated with a strong hereditary
component and 15–25% of familial aggregations are due to mutations in the BRCA1 (MIM# 113705)
or BRCA2 (MIM# 600185) genes [4–7]. Recent estimates have assessed that women who inherit
a mutation in BRCA1 have a chance of 72% (95% confidence interval (CI), 65–79%) of developing BC
and of 44% (95% CI, 36–53%) of developing ovarian cancer (OC) in their lifetime. In BRCA2 mutation
carriers the percentages are similar for BC (44%; 95% CI, 36–53%), but lower for OC (17%; 95% CI,
11–25%) [8]. BRCA gene mutations may also predispose to the development of other cancers, such as
endometrial, pancreatic, colorectal, gastric, and skin cancer [9,10]. Genetic testing is thus essential
to identify at-risk individuals who can undergo paths aimed at ensuring early diagnosis and/or at
reducing the risk of cancers, including prophylactic surgery (mastectomy and/or oophorectomy).
Moreover, it has been demonstrated that patients with BRCA mutation and OC present a significantly
more favorable prognosis and pharmacological sensitivity to treatment with inhibitors of the enzyme
poly (ADP-ribose) polymerase (PARP) [11].
The use of BRCA mutation testing for purposes of therapeutic choices implies that genetic testing
is easily accessible for all patients who could benefit and that results are available in a timeframe
consistent with the clinical need. Next-generation sequencing (NGS) platforms, allowing the
simultaneous analysis of multi-gene panels, have significantly decreased the time required for genetic
testing, but a major critical issue for clinical application of results is still represented by variant
interpretation. Despite the testing of hundreds of thousands of patients worldwide, there is a significant
percentage (5–20%) of BRCA1/2 sequence changes that are classified as variants of uncertain significance
(VUS), i.e., alterations for which there is insufficient evidence of the effects on the function of the
gene product and disease risk [12]. Variant classification has greatly improved through the research
efforts of multidisciplinary international consortia such as the Evidence-based Network for the
Interpretation of Mutant Alleles (ENIGMA; http://enigmaconsortium.org/), which has collected
evidence on a large-scale basis, and through the application of multifactorial likelihood models that
take into account tumor characteristics and family-based genetic data [13]. However, given the large
size of the BRCA1/2 genes, many VUS are unique to only one or few patients and the amount of data
required for a reliable classification by multifactorial models is often lacking.
It has been previously demonstrated that many BRCA1/2 variants affect mRNA and generate
abnormal splicing products [14]. These variants are able to alter intronic splicing elements such as the
5’ and 3’ consensus sequences, the so-called “Cartegni consensus regions” [15], or exonic/intronic
regulatory elements; they can also introduce de novo splice sites or lead to the activation of cryptic
splice sites. The resulting aberrant transcript(s) can present partial/entire intronic retention or exon
exclusion with production of a premature termination codon (PTC) in most cases. This evidence
of a dysfunctional role for the identified variants can thus overcome the need for additional data
required for multifactorial likelihood analysis. Different in silico tools have been developed to predict
the consequences of intronic/exonic variants on normal mRNA splicing and select them for in vitro
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studies [16–18]. However, their predictions have been demonstrated to be highly reliable for variants
located in Cartegni-consensus regions, but less accurate for variants lying in elements such as the
exonic splicing enhancer (ESE) or branchpoints [19]. Laboratory tests, including transcript analysis and
minigene assay, have been demonstrated to represent powerful tools to assess pathogenicity of potential
spliceogenic variants and remain mandatory for the characterization of aberrant transcripts [14,20–36].
In the present study, we investigated the splicing impact of ten BRCA1/2 variants never before
characterized in patient mRNA: four at the nearly invariant GT/AG dinucleotides at 5’ and 3’ intron
ends (c.7618-2A>G, c.7806-2A>G, c.8331+1G>A and c.8331+2T>C in BRCA2), five in the adjacent
less conserved splicing regions (c.302-5T>C, c.441G>C and c.441+5A>G in BRCA1; c.68-5A>G and
c.476-3C>A in BRCA2), and one outside the Cartegni consensus sequence (c.213-14C>G in BRCA1).
Real-time quantitative PCR (qPCR) was employed to evaluate the relative contribution of the different
observed mRNA isoforms to the total transcript pool. A possible incomplete (“leaky”) spliceogenic
effect was investigated using exonic tag single nucleotide polymorphisms (SNPs) or minigene assays,
allowing the final assessment of pathogenicity according to the current guidelines of the ENIGMA
consortium [37].
2. Results
In the present study, we assessed the pathogenicity of ten unclassified variants in BRCA1/2
identified in index cases selected from families undergoing genetic counseling and genetic testing.
Nine variants were intronic (three in BRCA1 and six in BRCA2) and one was located at the last
nucleotide of BRCA1 exon 7. By patient mRNA analysis, aberrant splicing patterns were demonstrated
for eight variants (Figures 1 and 2 and Table 1). Different types of abnormalities were observed:
(1) alternative usage of canonical splice sites, including whole intron retention (c.441G>C in BRCA1)
(Figure 1A) and whole exon skipping (c.476-3C>A in BRCA2) (Figure 2A); (2) usage of de novo splice
sites (c.68-5A>G in BRCA2) (Figures 2B and 3A) and usage of cryptic splice sites (c.213-14C>G in BRCA1
and c.7618-2A>G, c.7806-2A>G, c.8331+1G>A and c.8331+2T>C in BRCA2) (Figures 1B and 2C–E). In all
cases, variant alleles produced transcripts leading to PTCs or in-frame deletions disrupting clinically
important domains. Quantitative imbalances between physiological isoforms and aberrant transcripts
were assessed by qPCR assays (Figures 1 and 2). Complete/partial effect on splicing was established
by the use of tag SNPs, whenever possible, or, alternatively, by monoallelic minigene assays, leading to
variant classification according to current guidelines (Figures 3 and 4) [37]. Consistent with in silico
predictions, for two variants (c.302-5T>C and c.441+5A>G in BRCA1) a spliceogenic effect was not
observed following patient mRNA analysis combined with methods preventing nonsense-mediated
decay (NMD), or assessing allele-specific expression by tag-SNP analysis (Supplementary Figure S1).
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Figure 1. mRNA analysis of spliceogenic BRCA1 variants. Amplified products were separated on 3% 
agarose gel and independently sequenced. Gel images, graphical representation, and exon–intron 
junction sequences of full-length (FL) and aberrant transcripts are shown in upper panels. Variants 
and RT-PCR primers locations are indicated by the arrows. qPCR results are shown as histograms 
displaying the relative expression of the full-length and aberrant transcript in the patient’s and 
controls’ samples (lower panels). (A) c.441G>C, causing the retention of intron 7 (∇ivs7). The 
aberrant transcript accounts for 0.34 (±0.11) of overall gene expression in the variant carrier (case #1) 
and is undetectable in controls. (B) c.213-14G>C, causing the retention of 59 nt at the 3′-end of intron 
5 (∇59nt). The aberrant transcript accounts for 0.13 (±0.05) of overall gene expression in the variant 
carrier (case #4) and is undetectable in controls. M, molecular weight marker (0.15–2.1 Kbp, Roche); 
C, healthy control sample; NTC, no template control. 
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in controls. M, molecular weight marker (0.15–2.1 Kbp, Roche); C, healthy control sample; NTC,
no template control.
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Figure 2. mRNA analysis of spliceogenic BRCA2 variants. Amplified products were separated on 3% 
agarose gel and independently sequenced. Gel images, graphical representation, and exon–intron 
junction sequences of full-length (FL) and aberrant transcripts are shown in upper panels. Variants 
and RT-PCR primers locations are indicated by the arrows. qPCR results are shown as histograms 
displaying the relative expression of the full-length and aberrant transcript in the patient’s and 
controls’ samples (lower panels). (A) c.476-3C>A, causing the up-regulation of the isoforms lacking 
exon 6 (Δ6) and exons 5 and 6 (∆5,6). The Δ6 transcript accounts for 0.36 (±0.15) and Δ5,6 for 0.23 
(±0.15) of overall gene expression in the variant carrier (case #2), and is nearly undetectable in 
controls. (B) c.68-5A>G variant, causing the retention of four nucleotide at the 3’-end of intron 2 
(∇4nt) and the up-regulation of the isoform lacking exon3 (∆3). The aberrant transcript, detectable 
exclusively in the variant case (case #3), accounts for 0.34 (±0.3) of overall gene expression. The ∆3 
isoform accounts for 0.07 (±0.24) of overall gene expression in the variant carrier, 0.08 (±0.08) in the 
c.68-7T>A sample, and 0.02 (±0.05) in controls. (C) c.7618-2A>G variant, causing the deletion of 44 nt 
at the 5’-end of exon 16 (∆44nt). The aberrant transcript accounts for 0.10 (±0.24) of overall gene 
expression in the variant carrier (case #5) and is undetectable in controls. (D) c.7806-2A>G, causing 
three different aberrant transcripts resulting from the deletion of 20 nt at the 5’end of exon 17 
(Δ20nt), of 69 nt at the 5’end of exon 17 (Δ69nt) and of whole exon 17 (Δ17). Only the Δ20nt 
transcript is detectable in the variant carrier (case #6) and accounts for 0.11 (±0.06) of overall gene 
expression and is barely detected in control samples. (E) c.8331+1G>A and c.8331+2T>C variants, 
causing the deletion of 151 nt at the 3’-end of exon 17 and of the whole exon 18 (Δ151nt_ex17 + Δ18), 
and the up-regulation of the isoforms resulting from the deletion of exon 18 (Δ18) and of exons 17 
and 18 (Δ17,18). The ∆151nt_ex17 + ∆18 transcript accounts for 0.09 (±0.001) and 0.04 (±0.06) of 
overall gene expression in c.8331+1G>A (case #7) and c.8331+2T>C (case #8) samples, respectively, 
and is undetectable in controls. The ∆18 transcript accounts for 0.23 (±0.2), 0.34 (± 0.09) and 0.03 
(±0.21) of overall gene expression in case #7, case #8 and controls, respectively. The ∆17,18 transcript 
is undetectable in both variant cases and controls. M, molecular weight marker (0.15–2.1 Kbp, Roche 
and ΦX174 DNA/BsuRI (HaeIII) Marker, Thermo Scientific); C, healthy control sample; NTC, no 
template control. 
Figure 2. R analysis of spliceogenic BRCA2 variants. Amplified products were separated on 3%
agarose gel and independently sequenced. Gel i ages, graphical representation, and exon–intron
junction sequences of full-length (FL) and aberrant transcripts are shown in upper panels. Variants and
RT-PCR primers locations are indicated by the arrows. qPCR results are shown as histograms displaying
the relative expression of the full-length and aberrant transcript in the patient’s and controls’ samples
(lower panels). (A) c.476-3C>A, causing the up-regulation of the isoforms lacking exon 6 (∆6) and exons
5 and 6 (∆5,6). The ∆6 transcript accounts for 0.36 (±0.15) and ∆5,6 for 0.23 (±0.15) of overall gene
expression in the variant carrier (case #2), and is nearly undetectable in controls. (B) c.68-5A>G variant,
causing the retention of four nucleotide at the 3’-end of intron 2 (∇4nt) and the up-regulation of the
isoform lacking exon3 (∆3). The aberrant transcript, detectable exclusively in the variant case (case #3),
accounts for 0.34 (±0.3) of overall gene expression. The ∆3 isoform accounts for 0.07 (±0.24) of overall
gene expression in the variant carrier, 0.08 (±0.08) in the c.68-7T>A sample, and 0.02 (±0.05) in controls.
(C) c.7618-2A>G variant, causing the deletion of 44 nt at the 5’-end of exon 16 (∆44nt). The aberrant
transcript accounts for 0.10 (±0.24) of overall gene expression in the variant carrier (case #5) and is
undetectable in controls. (D) c.7806-2A>G, causing three different aberrant transcripts resulting from
the deletion of 20 nt at the 5’end of exon 17 (∆20nt), of 69 nt at the 5’end of exon 17 (∆69nt) and of whole
exon 17 (∆17). Only the ∆20nt transcript is detectable in the variant carrier (case #6) and accounts for
0.11 (±0.06) of overall gene expression and is barely detected in control samples. (E) c.8331+1G>A
and c.8331+2T>C variants, causing the deletion of 151 nt at the 3’-end of exon 17 and of the whole
exon 18 (∆151nt_ex17 + ∆18), and the up-regulation of the isoforms resulting from the deletion of
exon 18 (∆18) and of exons 17 and 18 (∆17,18). The ∆151nt_ex17 + ∆18 transcript accounts for 0.09
(±0.001) and 0.04 (±0.06) of overall gene expression in c.8331+1G>A (case #7) and c.8331+2T>C (case
#8) samples, respectively, and is undetectable in controls. The ∆18 transcript accounts for 0.23 (±0.2),
0.34 (± 0.09) and 0.03 (±0.21) of overall gene expression in case #7, case #8 and controls, respectively.
The ∆17,18 transcript is undetectable in both variant cases and controls. M, molecular weight marker
(0.15–2.1 Kbp, Roche and ΦX174 DNA/BsuRI (HaeIII) Marker, Thermo Scientific); C, healthy control
sample; NTC, no template control.
Cancers 2019, 11, 295 7 of 22
Table 1. mRNA splicing effects of identified variants and predicted effect on protein.
Gene
Variant (Human Genome
Variant Society, HGVS)
Chromosome Position
(GRCh37)
Location
ClinVar
Classification
(Entries) *
Methods Observed Effect on Splicing Effect on mRNA (HGVS) Effect on Protein(HGVS)
Complete/Partial
Effect (Method) Splice Class
†
Variant
Classification
According to
Published
Guidelines §
BRCA1
c.213-14C>G
Chr17:g.41256987G>C Intron 5 VUS (2) PAXgene
retention of 59nt at 3′-end of
intron 5
r.[212_213ins213-59_213-1;
213-14c > g] p.Arg71Serfs*11
Partial
(minigene) 2S Class 3
c.302-5T>C
Chr17:g.41256283A > G Intron 6 VUS (1) PAXgene no effect NA NA NA 1S Class 2
c.441G>C
Chr17:g.41256139C>G Exon 7
LP (1)/VUS
(3) PAXgene retention of intron 7
r.[441_442ins441+1_442-1; 441g
> c] p.Gln148Valfs*21
Partial
(exonic tag SNP) 2S Class 3
c.441 + 5A>G
Chr17:g.41256134T>C Intron 7 NP PAXgene no effect NA NA NA 1S Class 2
BRCA2
c.68-5A>G
Chr13:g.32893209A>G Intron 2 VUS (1) lymphocytes
retention of 4nt at 3′-end of
intron 2;
up-regulation of ∆3 isoform
r.[67_68ins68-4_68-1];
↑ r.[68_316del]
p.[Leu24Argfs*7];
↑
p.[Asp23_Leu105del]
Partial
(minigene) 3S Class 3
c.476-3C>A
Chr13:g.32900376C>A Intron 5
P (1)/VUS
(1) LCL
up-regulation of ∆5,6 and ∆6
isoforms
↑ r.[426_516del];
↑ r.[476_516del]
↑ p.[Ser142Argfs*13];
↑p.[Val159Glyfs*10];
Partial
(exonic tag SNP) 2S Class 3
c.7618-2A>G
Chr13:g.32931877A>G Intron 15 P (1)/LP (1) PAXgene
skipping of 44nt at 5′-end of
exon 16 r. [7618_7661del] p.[Leu2540Glnfs*11]
Complete
(minigene) 3S Class 5
c.7806-2A>G
Chr13:g.32936658A>G Intron 16 P (8)/LP (1) LCL
skipping of 20nt at 5′-end of
exon 17; skipping of 69nt at
5′-end of exon 17; skipping of
exon 17
r.[7806_7825del];
r.[7806_7874del];
r. [7806_7976del]
p.[Ala2603Cysfs*8];
p.[Ala2603_Arg2625del];
p.[Ala2603Serfs*3]
Complete
(exonic tag SNP) 3S Class 5
c.8331 + 1G > A
Chr13:g.32937671G>A Intron 18 P (3)/LP (1) LCL
skipping of 151nt at 3′-end of
exon 17 and skipping of ex18;
up-regulation of ∆ex17,18 and
∆ex18 isoforms
r.[7826_8331del];
↑ r.[7806_8331del];
↑ r.[7977_8331del];
p.[Gly2609Aspfs*4];
↑ p.[Ala2603Phefs*43];
↑ p.[Tyr2660Phefs*43];
Partial
(exonic tag SNP) 2S 3
c.8331+2T>C
Chr13:g.32937672T>C Intron 18 P (5)/LP (1) LCL
skipping of 151nt at 3′-end of
exon 17 and skipping of ex18;
up-regulation of ∆ex17,18 and
∆ex18 isoforms
r.[78268331del];
↑ r.[7806_8331del];
↑ r.[7977_8331del]
p.[Gly2609Aspfs*4];
↑ p.[Ala2603Phefs*43];
↑ p.[Tyr2660Phefs*43];
Partial
(exonic tag SNP) 2S 3
* Clinvar (URL: https://www.ncbi.nlm.nih.gov/clinvar/; last update 26 January 2019). VUS, variants of uncertain significance; LP, likely pathogenic; NP not provided; P, pathogenic; LCL,
lymphoblastoid cell line; † Class 1S, no effect on splicing; Class 2S, leaky splice site variant: partial effect; Class 3S, severe impact on splicing: the mutant variant does not produce naturally
occurring functional transcripts [19]. § Class 5, pathogenic; Class 4, likely pathogenic; Class 3, uncertain; Class 2, likely not pathogenic or of little clinical significance; § according to [37];
NA, not applicable.
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Figure 3. RT-PCR analysis of the BRCA1 and BRCA2 minigene constructs expressed in HeLa cells using vector specific primers. A schematic representation of the hybrid minigene 
constructs is depicted on the left; the dotted lines indicate normal splicing. Each construct contains the exon close to, or harboring the variant of interest and part of the upstream and 
downstream introns of BRCA1 or BRCA2 genes. Electropherograms of the spliced transcripts are shown on the right. (A) The construct contains exon 3 of the BRCA2 gene. c.68-5A>G, 
construct containing the c.68-5A>G variant. (B) The construct contains exon 6 of the BRCA1 gene. c.213-14C>G, construct containing the c.213-14C>Gvariant. (C) The construct contains 
exon 16 of the BRCA2 gene. c.7618-2A>G, construct containing the c.7618-2A>G variant. M, 1 kb plus molecular marker (Invitrogen); Empty, empty β-globin-pCDNA3.1 vector; WT, 
wild-type construct.  
Figure 3. RT-PCR analysis of the BRCA1 and BRCA2 minigene constructs expressed in HeLa cells using vector specific primers. A schematic representation of the
hybrid mi igene constructs is d picte on th left; the dotted ines indi ate normal splicing. Each construct contains the exon close to, r arbo ing the variant
of interest and part of the upstream and downstream introns of BRCA1 or BRCA2 genes. Electropherograms of the spliced transcripts are shown on the right.
(A) The construct contains exon 3 of the BRCA2 gene. c.68-5A>G, construct containing the c.68-5A>G variant. (B) The construct contains exon 6 of the BRCA1 gene.
c.213-14C>G, construct containing the c.213-14C>Gvariant. (C) The construct contains exon 16 of the BRCA2 gene. c.7618-2A>G, construct containing the c.7618-2A>G
variant. M, 1 kb plus molecular marker (Invitrogen); Empty, empty β-globin-pCDNA3.1 vector; WT, wild-type construct.
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Figure 4. Determination of partial/total effect by SNP Sanger sequencing in the full-length (FL) 
transcripts from PAXgene samples (panel A) or LCLs (panels B, C, D, and E). Primers are shown in 
Supplementary Table S3. The arrows indicate the investigated SNPs. 
2.3. Usage of Cryptic Splice Sites 
The c.213-14C>G variant in BRCA1, reported as VUS in ClinVar (Table 1), was predicted by all 
Alamut tools to activate a cryptic 3′ splice site at position c.213-59. In addition, three out of five 
interrogated tools (SSF, MES and HSF) predicted the creation of a de novo 3′ splice site at c.213-13 
with a lower score respect to the cryptic site (Table 2). In vitro analyses revealed an abnormal 
product consisting of the out-of-frame retention of 59 bases at the 3′ end of intron 5 (Figure 1B). This 
partial intronic retention creates a premature stop codon with loss of all functional domains 
(p.(Arg71Serfs*11)). qPCR showed a low relative decrease of the full-length transcript in patient 
compared to control samples (87% vs. 100%) and that the aberrant product, totally absent in controls, 
Figure 4. Determination of partial/total effect by SNP Sanger sequencing in the full-length (FL)
transcripts from PAXgene samples (panel A) or LCLs (panels B–E). Primers are shown in Supplementary
Table S3. The arrows indicate the investigated SNPs.
2.1. Alternative Usage of Canonical Splicing Sites
One variant in BRCA1 (c.441G> ), aff cting the last nucleotide of exon 7, and for which conflicting
interpre ations of pathogenicity are re orted in ClinVar (Table 1), was pre cted by two out of five
in silico analyses to damage the donor s lice site (Table 2). Firstly, th hyp the is of exon 7 skipping
as tested, but th d tection of no alteration led us to postulate an intronic t ntion. The RT-PCR
experiment for i tr nic retention showed the presence of an berrant splicing p duct consisting of the
whole i tro 7 exonization, predicted to res lt in an early truncated protein lacki g most functio al
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domains (p.(Gln148Valfs*21)) (Figure 1A). qPCR quantified a contribution of full-length and aberrant
transcript to the total BRCA1 expression of 66% and 34%, respectively. No intron 7-retaining transcript
was found in controls (Figure 1A). The use of the exonic variant itself (c.441G>C) as tag-SNP analysis
allowed for the determination of a partial splicing effect (Figure 4A).
The c.476-3C>A variant in BRCA2, occurring at the 3’ splice site of intron 5 and reported
with conflicting interpretations of pathogenicity in ClinVar (Table 1), was predicted to impair the
canonical acceptor site by all bioinformatic tools (Table 2). Analysis of patient’s RNA showed that
the variant leads to the increase of two naturally occurring isoforms with different out-of-frame
deletions: one lacking exon 6 (∆6) and the other lacking both exons 5 and 6 (∆5,6) (Figure 2A) [38].
Both transcripts result in early truncated proteins, defective of all functional domains. By qPCR all
isoforms were quantified in patient sample and controls. Quantitative analysis showed that both
alternative isoforms (∆6 and ∆5,6), barely detectable in controls, were highly expressed in patient
sample, at levels comparable with the full-length transcript (Figure 2A). Using an exonic tag SNP
(c.1114A>C; p.(Asn372His)), we demonstrated that canonical transcript mostly derives from wild-type
allele but a very small peak corresponding to the SNP variant associated with the mutant allele was
observed, indicating a minimal “leaky” effect (Figure 4B).
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Table 2. In silico analyses for variants leading to the usage of cryptic/de novo splice sites.
Variant Location, SS,Distance
Canonical SS Used Cryptic SS (Location, SS) De Novo SS
Wt > Mut (% Variation) Score Score
MES SSF NNSPLICE GeneSplicer HSF MES SSF NNSPLICE GeneSplicer HSF MES SSF NNSPLICE GeneSplicer HSF
Gene:BRCA1
c.213-14C>G
intron 5, 3′, 14 c.213-59 (intron 5, 3
′) c.213-13 (intron 5, 3′)
4.84 > 2.23
(−53.9%)
85.51 > 83.10
(−2.8%) NP NP =89.39 10.23 86.74 0.97 5.90 82.22 2.06 79.09 NP NP 80.34
c.302-5T>C Intron 6, 3′, 5 11.7 > 11.2(−4.4%)
91.5 > 88
(−3.9%)
0.99 > 0.98
(−0.7%)
8.4 >
7.5
(−11%)
NP None None
c.441G>C exon 7, 5′, 1 3.2 > - NP NP NP 78.8 > 67.8(−14%) None None
c.441+5A>G Intron 7, 5′, 5 3.2 > 8.8(+173.7%) - >82.0 - >1.0 - >2.9 NP None None
Gene:BRCA2
c.68-5A>G
intron 2, 3′, 5 6.10 > 0.68(−88.9%) 87.89> -
0.94 > 0.93
(−1.0%) NP
80.63 > 80.56
(−0.1%) None
c.68-4 (intron 2, 3′)
6.12 88.92 0.96 NP 96.85
c.476-3C>A Intron 5, 3′, 3 10.49 > 6.02(−42.6%)
88.73 > 78.77
(−11.2%) 0.91> - 2.02> -
91.61 > 82.22
(−10.2%) None None
c.7618-2A>G intron 15, 3′, c.7662 (exon 16, 3
′)
NP
7.11>- 86.07 > - 0.69 > - 3.17 > - 79.10 > - 1.53 NP NP NP 73.60
c.7806-2A>G intron 16, 3′, 2 8.33 > - 98.45 > - 0.95 > - 3.73 > - 91.03 > -
c.7826 (exon 17, 3′)
NP5.95 78.60 NP NP 87.97
c.7875 (exon 17, 3′)
5.03 72.60 0.54 NP 78.95
c.8331+1G>A
c.8331+2T>C
Intron 18, 5′, 1
Intron 18, 5′, 2
8.88 > - 87.54> - 0.96> - 2.27> - 86.88> - c.7826 * (exon 17, 5′)
NP
8.88> 87.54 > 87.12(−0.5) 0.96> 2.27> 86.88> 6.34 80.45 0.94 NP 88.10
In silico analysis was performed using five prediction tools (Max Ent Scan, Splice Site Finder-like, NNSPLICE, GeneSplicer, Human Splicing Finder). -, SS abolished by the variant; NP, not
predicted. Thresholds: MaxEnt, (0–12) for the 5′SS and (0–16) for the 3′SS, SSF (0–100), NNSPLICE (0–1), GeneSplicer (0–15), HSF (0–100). * This position is outside the range of prediction
of Alamut Visual (199 bp), so data relative to this cryptic splice site were collected a posteriori, after the experimental analysis of the splicing pattern.
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2.2. Usage of A De Novo Splice Site
The c.68-5A>G substitution in BRCA2, reported as VUS in Clin Var, (Table 1), reduces the strength
of the canonical 3′ splice site in intron 2 and simultaneously generates an alternative acceptor splice site
four nucleotides upstream, predicted by four out of five in silico tools (SSF, MES, NNSPLICE and HSF)
(Figure 2B and Table 2). The usage of this de novo splice site generates an isoform predicted to result
in an early stop of translation with the consequently loss of all protein domains (p.(Leu24Argfs*7))
(Figure 2B). Simultaneously, the variant up-regulates the naturally occurring BRCA2 isoform carrying
the in-frame skipping of exon 3 (∆3) (Figure 2B). Expression quantification by qPCR revealed that the
c.68-5A>G variant induces an increase of ∆3 isoform (7% of the total transcript comparable to the one
induced by the c.68-7T>A variant found in another patient of our cohort (8% of the total transcript) vs.
2% in controls (mean value of ten samples) (Figure 2B). Minigene assay confirmed the generation of
the out-of-frame isoform with the inclusion of four intronic nucleotides, but failed to detect the ∆3
isoform possibly due to the short sequence included in the construct that contains exon 3 and partial
intronic flanking regions. The latter might not be enough to allow an alternative splicing mechanism.
Sequencing of minigene product showed a very low level of full-length transcript produced from the
mutated allele (Figure 3A and Table 1).
2.3. Usage of Cryptic Splice Sites
The c.213-14C>G variant in BRCA1, reported as VUS in ClinVar (Table 1), was predicted by
all Alamut tools to activate a cryptic 3′ splice site at position c.213-59. In addition, three out of
five interrogated tools (SSF, MES and HSF) predicted the creation of a de novo 3′ splice site at
c.213-13 with a lower score respect to the cryptic site (Table 2). In vitro analyses revealed an abnormal
product consisting of the out-of-frame retention of 59 bases at the 3′ end of intron 5 (Figure 1B).
This partial intronic retention creates a premature stop codon with loss of all functional domains
(p.(Arg71Serfs*11)). qPCR showed a low relative decrease of the full-length transcript in patient
compared to control samples (87% vs. 100%) and that the aberrant product, totally absent in controls,
contributed for 13% of the total BRCA1 expression (Figure 1B). Hybrid minigene assay displayed
a partial spliceongenic effect (Figure 3B). No effect due to the predicted creation of an alternative splice
site at c.213-13 was observed.
The c.7618-2A>G variant in BRCA2, reported as pathogenic or likely pathogenic in ClinVar
(Table 1), was predicted by all in silico tools to abolish the canonical 3′ splice site (Table 2). By RT-PCR
we demonstrated the skipping of 44 nt at the 5′-end of exon 16 due to the activation of an exonic
cryptic acceptor site (Figure 2C) predicted by only two (MES and HSF) out of five in silico tools
(Table 2). The predicted effect on the protein was the disruption of the DNA-binding domain
(DBD) (p.(Leu2540Glnfs*11)). qPCR demonstrated a low contribution (10%) of the mutant transcript
(∆44nt-ex16) to the total gene expression (Figure 2C). Minigene assay confirmed the splicing pattern
observed in patient’s mRNA and demonstrated a total spliceogenic effect (Figure 3C).
The BRCA2 c.7806-2A>G variant, pathogenic or likely pathogenic in ClinVar (Table 1), was strongly
predicted by all the in silico tools to abolish the natural acceptor splice site. In addition, the activation
of two cryptic splice sites at positions c.7826 and c.7875 was predicted (Table 2). The in vitro analysis
confirmed a complex abnormal splicing pattern leading to the production of three different isoforms
which include the whole deletion of exon 17 (∆17), and the partial deletion of either 20 or 69 nucleotides
at the 5′-end of exon 17 (∆20nt-ex17 and ∆69nt-ex17) (Figure 2D). All alternative transcripts lead to the
disruption of the DBD domain. The relative amount of each transcript on the total BRCA2 expression
was investigated by qPCR. The ∆20nt-ex17 transcript accounted for 10% of overall expression in the
case sample and is quite absent in controls, while ∆69nt-ex17 was barely detected in the case and
totally absent in controls. Quantification of ∆17 was not possible by qPCR, in both the case and
controls, probably due to the very low expression levels. The analysis of the c.7397 tag SNP in exon 14,
showing mono-allelic expression of the full-length transcript, proved a total spliceogenic effect of the
variant considered (Figure 4C).
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The two alterations affecting the invariant dinucleotides at the 5′ end of intron 18 of BRCA2,
c.8331+1G>A and c.8331+2T>C, were predicted by five and four in silico tools, respectively, to abolish
the corresponding natural donor splice site (Table 2). Both variants are classified as pathogenic or
likely pathogenic in ClinVar (Table 1). The in vitro characterization confirmed in both cases the same
abnormal splicing pattern consisting in the skipping of the last 151 bp of exon 17 and of the whole exon
18 (∆151nt_ex17 + ∆18), in addition to the increase of the two naturally occurring isoforms involving
exon 18 (∆18 and ∆17,18) (Figure 2E) [38]. Quantification by qPCR of all detected transcripts revealed
the relative decrease of the full length BRCA2 mRNA in patient samples (67% for c.8331 + 1G > A and
61% for c.8331+2T>C vs. 96% in healthy control samples). The ∆18 isoform was found up-regulated
in both samples (23% and 34% in c.8331+1G>A and c.8331+2T>C, respectively, vs. 3% in controls),
while the lowly expressed ∆17,18 isoform could not be quantified both in samples and controls.
The aberrant transcript lacking the last 151 bp of exon 17 and the entire exon 18, not expressed
in controls, was shown to contribute for 9% and 4% of the total expression in c.8331+1G>A and
c.8331+2T>C carriers, respectively. The analysis of the c.7242A>G tag SNP in exon 14 demonstrated
a bi-allelic expression of the full-length transcript in both cases (Figure 4D,E).
2.4. No Splicing Effect
For two variants in BRCA1, namely c.302-5T>C and c.441+5A>G, located in the 3′ and 5′ Cartegni
consensus regions of intron 6 and intron 7, respectively, we did not detect any splicing aberration,
as expected by the in silico prediction (Supplementary Figure S1).
For the c.441+5A>G, the use of an exonic tag SNP (c.4308T > C) allowed to demonstrate biallelic
expression (Supplementary Figure S1B). No exonic tag SNPs were available for the c.302-5T>C variant.
Analysis of minigene expressed in cells treated with puromycin to prevent potential degradation
of unstable transcripts via NMD [33], confirmed the presence of only the full-length transcript
(Supplementary Figure S1A).
3. Discussion
BRCA1 and BRCA2 genetic test is fundamental for counseling and clinical management
of high-risk breast-ovarian families. Massive parallel sequencing has greatly accelerated the
analysis and the diagnostic process is generally straightforward for protein-truncating mutations.
However, the interpretation of the biological consequences of the other types of variants still represents
a challenge, creating problems in the clinical setting. Given that a significant fraction of VUS can
have spliceogenic effects, transcript analysis represents an important tool to assess pathogenicity.
Here, by patients′ mRNA analysis, we characterized the impact on splicing of ten BRCA1/2 variants.
For all these variants, multifactorial likelihood analysis was not applied due to the lack of sufficient
data. Eight variants were demonstrated to impact on the normal splicing process and aberrant
transcripts were characterized. Different types of abnormal splicing events were observed, including
intron retention (c.441G>Cin BRCA1), exon skipping (c.476-3C>A in BRCA2), and alternative 5′ or 3′
splice site activation (c.213-14C>G in BRCA1 and c.68-5A>G, c.7618-2A>G, c.7806-2A>G c.8331+1G>A,
c.8331+2T>C in BRCA2), leading to transcripts with PTCs or in-frame loss of functionally important
residues. Partial/complete splicing impact and quantitative contribution of different transcripts were
assessed leading to variants classification according to current guidelines developed by the ENIGMA
consortium [37].
We demonstrated that the c.441G>C variant in BRCA1 causes the retention of intron 7. In the
absence of in vitro studies assessing allele-specific transcript expression, this variant, causing G > non-G
substitution at the last base of the exon and with the first 6 bases of the intron not being GTRRGT,
would have been considered of Class 4 (likely pathogenic) [37]. In the present study, the usage of
the variant itself as a tag-SNP allowed to reveal a partial splicing effect, leading to a Class 3 (VUS)
reassignment, in accordance with ENIGMA guidelines [37]. As to the c.476-3C>A variant in BRCA2,
we observed the up-regulation of transcripts carrying the out-of-frame deletions of exon 6 (∆6) and
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exons 5–6 (∆5–6). Both isoforms were barely detectable in control samples, in accordance with previous
studies reporting these exon-skipping events as naturally occurring at low expression levels [21,33,38].
Up-regulation of these non-functional products had been previously reported in association with the
c.476-2A>G, c.516G>A and c.516+1G>T pathogenic BRCA2 variants [28,33,39]. By real-time qPCR,
we demonstrated that the c.476-3C>A variant causes the up-regulation of both alternative isoforms
at a level comparable with that of the full-length transcript. Since a minimal “leaky” effect was
demonstrated by the use of an exonic tag SNP, current guidelines indicate to consider the variant of
Class 3 and recommend multifactorial likelihood analysis to assess a definitive pathogenic role [37].
Concerning the activation of alternative splice sites, we found that the c.68-5A>G variant in BRCA2,
creating a de novo acceptor splice site four nucleotides upstream exon 3, leads to the production of an
out-of-frame transcript predicted to result in an early interruption of translation (p.(Leu24Argfs*7)).
Simultaneously, we observed an up-regulation of a naturally occurring BRCA2 isoform carrying the
in-frame skipping of exon 3 (∆3). In accordance with previous data [38–40], the ∆3 isoform was present
in our control samples, representing a non-negligible fraction of the total transcript. The extent of
up-regulation of the ∆3 isoform in the presence of the c.68-5A > G variant (approximately 7%) was
comparable with that found in one patient carrying the already reported c.68-7T>A BRCA2 variant
(approximately 8%). The c.68-7T>A substitution has been the object of intense debate concerning its
pathogenetic role [14,19,27,40,41], but a recent article finally classified it as benign [42]. The c.68-5A>G
variant here identified, with respect to the c.68-7T>A substitution, generated an additional transcript
containing an early PTC. The up-regulation of the in-frame alternative ∆3 isoform may raise concerns
about the clinical impact of the variant. However, exclusive expression of the ∆3-transcript from one
allele has been demonstrated to be associated with a high risk of breast and/or ovarian cancer [40,41].
In fact, residues encoded by exon 3 have been demonstrated to be important for the interaction with
PALB2, a cofactor essential for the nuclear localization of the BRCA2 protein, the interaction with
BRCA1, the recruitment of RAD51 to the DNA double strand breaks (DSBs), and the protection
of the replication forks. In fact, the disruption of the interaction between PALB2 and BRCA2 has
been demonstrated to impair the DNA DSBs repair function [41,43–46]. Moreover, the results from
multifactorial likelihood analysis of six BRCA2 variants leading to full exon 3 skipping strongly
inclines in favor of a pathogenic role of these variants [41]. Notwithstanding, minigene analysis
revealed the expression the of full-length transcript from the mutated allele, although at very low level,
which, formally does not allow to classify the c.68-5A > G variant as pathogenic, in the absence of
additional evidences.
Activation of cryptic splice sites was demonstrated for the remaining five spliceogenic variants
(c.213-14C>G in BRCA1 and c.7618-2A>G c.7806-2A>G c.8331+1G>A, c.8331+2T>C in BRCA2).
The c.213-14C>G variant in BRCA1 was predicted to weaken canonical splicing and to activate
a cryptic 3′ splice site. Patient mRNA analysis confirmed the prediction and showed the out-of-frame
retention of 59 bp at the 3′ end of intron 5. The usage of the same cryptic acceptor site had been
previously reported for the c.213-11T>G pathogenic variant, suggesting that this site is preferentially
used when the canonical one is weakened or eliminated [33]. The exonization of this part of intron
5 is associated with a very low expression level of the resulting transcript, compared to full-length,
as shown by quantitative expression analysis. This is consistent with the evidence of the partial
splicing effect detected by minigene assay and supports the classification of the variant as Class
3 [37]. The c.7618-2A>G variant in BRCA2, predicted by all in silico tools to abolish the canonical
3′ splice site, showed an aberrant out-of-frame transcript devoid of the first 44 nt of exon 16, due to
the activation of a cryptic exonic splice site predicted by only two out of five prediction tools (MES
and HSF). The contribution of the aberrant transcript to the total gene expression was very low
(approximately 10%) suggesting a possible role of NMD in triggering the degradation of the mutant
transcript in patient’s cell lines. However, this possibility was not experimentally verified by puromycin
treatment. The same aberration had been previously demonstrated for the adjacent c.7618-1G>A
pathogenic variant [28]. Since no informative (heterozygous) BRCA2 exonic SNPs were present in
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carrier of the c.7618-2A>G, allele-specific expression was assessed by minigene assay, which represents
a valuable tool to guide clinical classification of spliceogenic variant in cases where tag-SNP analyses
cannot be performed. The assay showed the production of only the mutant transcript, allowing the
classification of the variant as pathogenic. The c.7806-2A>G variant in BRCA2, predicted by all the
in silico tools to abolish the canonical 3′ splice site, in addition to the skipping of exon 17, leads to
the activation of two exonic cryptic splice sites, producing two transcripts lacking respectively 20
and 69 nt at the 5′-end of exon 17. All the produced mRNAs carry a PTC leading to the loss of the
DBD. Noticeably, in a previous investigation of the variant, only the transcript missing 20 nt was
observed, whereas the two transcripts lacking the entire exon 17 and the 69 nt at the 5′-end of the
exon were not detected [19]. The ratio of the total amount of the aberrant transcripts, taken together,
to the total BRCA2 expression was very low (~10%). Given the exclusion of a leaky effect of the
mutation by tag-SNP analysis, we can hypothesize a massive degradation of the aberrant transcripts
possibly induced by the formation of PTCs. However, also for this sample puromycin treatment was
not performed. These findings, obtained by a direct patient’s mRNA analysis, are concordant with
the data obtained with the minigene assay by Fraile-Bethencourt et al. [36], and contribute to the final
classification of the described variant as pathogenic, given that no full-length transcript was found to
be produced by the mutated allele. The two variants c.8331+1G>A and c.8331+2T>C, both predicted to
abolish the canonical exon 18 donor splice site, generate three mis-spliced transcripts, each carrying
a PTC. Two of these transcripts (∆18 and ∆17,18) are reported as naturally occurring variants, found in
normal samples at low levels [38]. Quantitative analysis showed a relative increase of ∆18 isoform
in cases respect to controls, while neither in cases nor in controls the amount of the ∆17,18 isoform
was detected by qPCR, probably due to technique limitations. The third transcript, showing the loss
of 151 bp at exon 17 3′-end and of exon 18 (∆151nt_ex17 + ∆18), was generated by the usage of an
exonic cryptic splice site, probably activated following the loss of the canonical donor site of exon 18.
This transcript is exclusively expressed in cases and its contribution to the overall BRCA2 expression is
higher in the c.8331+1G>A carrier (9%) than in the c.8331+2T>C carrier (4%). The alternative transcripts
overall contribute to the total BRCA2 expression for 32% and 38% in c.8331+1G>A and c.8331+2T>C,
respectively. These two variants affect the same splice site of the c.8331+1G>T, previously reported to
induce aberrant splicing and classified as pathogenic by Fraile-Bethencourt et al. [36]. In the same study,
these authors classified as pathogenic also the c.8331+2T>C, based on the observation, by minigene
assay, of no full-length expression by the mutated allele. By contrast, in our study, tag-SNP analysis
revealed the expression of the normal transcript from both the wild-type and the mutated allele.
While this discrepancy could be attributed to the different approaches used in the two studies to assess
allele-specific expression, our results argue against a classification of the c.8331+2T>C as pathogenic
(Class 5). The same applies also to the c.8331+1G>A, which in our hands displays a bi-allelic full-length
expression. Therefore, in our opinion, in the absence of further evidences, both the above variants
should be classified at present as “uncertain” (Class 3), according to the ENIGMA guidelines [37].
This study allowed the assessed for the first time the complete aberrant splicing effect in patients’
mRNA for the c.7618-2A>G and c.7806-2A>G BRCA2 variants, providing strong evidence of their
pathogenicity. These findings have important consequences for families in terms of preventive and
prophylactic measures, as well as targeted therapies such as those based on the use of PARP-inhibitors.
In accordance with in silico prediction, we demonstrated that the c.441+5A>G and c.302-5T>C variants
in BRCA1 have no splicing impact, allowing a final classification as likely benign [37]. Finally, due to
evidences of a partial splicing effect, six variants (c.213-14C>G, c.441G>C in BRCA1 and c.68-5A>G,
c.476-3C>A, 8331+1G>A and 8331+2T>C in BRCA2) remain of Class 3 in accordance with current
interpretation guidelines [37]. This conservative criterion is justified considering that spliceogenic
variants preserving the ability to synthesize a normal (full-length) transcript do not completely abrogate
the synthesis of a normal protein and might maintain a tumor suppressor activity [25]. At least in
some instances, these alterations might be associated with a lower tumor risk, compared to classical
pathogenic BRCA gene variants. This justifies caution in patients’ management although, if present
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in patients with ovarian cancer, they could anyhow be targeted by PARP inhibitors, in view of the
potential beneficial effect of such therapy.
4. Patients and Methods
4.1. Patients
Patients were selected among those who attended three different Italian centers (Azienda
Ospedaliera Universitaria Senese, Fondazione IRCCS, Istituto Nazionale dei Tumori (INT) of Milan,
Azienda Ospedaliero-Universitaria di Modena) for genetic counseling and BRCA1/BRCA2 testing.
Genetic analysis was offered based on individual and/or family history according to updated
National Comprehensive Cancer Network (NCCN) guidelines (NCCN Clinical Practice Guidelines
in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian) or local inclusion
criteria [47]. Sporadic cases of OC accessed to the molecular analysis on the basis of national
recommendations [48]. After a first DNA-level analysis performed by massive parallel sequencing
(Ion Torrent PGM, Life Technologies, Carlsbad, CA, USA), or conventional Sanger sequencing,
patients with VUS that could potentially alter the mRNA splicing process were selected for in vitro
studies. The significance and consequences of VUS identification were discussed with patients in
post-test counseling. New blood samples were thus collected in order to investigate the pathogenicity
of the variants by transcript analysis. Informed consent was obtained prior to testing and the study
was approved 28 January 2015 by the local Ethics Committee of the Istituto Nazionale Tumori (INT);
ethic code: N. INT 7/15.
4.2. Methods
4.2.1. In Silico Splicing Analysis
Five tools integrated in the Alamut Visual software application (Interactive Biosoftware,
Version 2.7, Rouen, France) were used for in silico prediction of the impact on the splicing process:
Splice Site Finder-like (SSF), MaxEntScan (MES) Splice Site Prediction by Neural Network (NNSPLICE)
GeneSplicer (GS) and Human Splicing Finder (HSF) [16,49–53].
4.2.2. Cell Cultures
Mononuclear cells were isolated from 5 mL of peripheral blood supplemented with Ficoll.
Epstein-Barr virus (EBV)-immortalized human lymphoblastoid cell lines (LCLs) were established
and grown as previously reported [33].
4.2.3. RNA Extraction and Reverse Transcriptase-PCR (RT-PCR)
Depending on the strategies used in the participating laboratories, different protocols of RNA
extraction from blood were used. Total RNA was isolated from PAXgene blood RNA tubes
(PreAnalytiX®, Qiagen, Hilden, Germany) (http:/www.qiagen.com), with PAXgene Blood RNA
Kit (IVD) (PreAnalytiX®), following the manufacturer’s instructions and quantified by NanoDrop 2000
Spectrophotometer (Thermo Scientific). For each sample, 1 µg of RNA was reverse-transcribed into
cDNA using a dedicated Qiagen kit (QuantiTect®Reverse Transcription Kit, Qiagen) according to the
manufacturer’s instructions. RNA from LCLs was extracted and reversed transcribed as described [42].
cDNA was stored at −20 ◦C until use.
4.2.4. Transcript Characterization
In order to verify the effect of considered VUS on BRCA gene splicing, specific PCR primers
were designed (Supplementary Table S1). For each amplification, a free-cDNA sample and five
normal control cDNA samples were included. PCRs were performed using GoTaq DNA Polymerase
reagents (5× GoTaq Flexi buffer; 25 mM MgCl2, GoTaq Hot Start Polymerase), in addition with 2 mM
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dNTPS, milliQ H2O and 100 ng of cDNA, for a final volume of 50 µL. Amplification was performed in
a Thermal Cycler 2720 (Applied Biosystem, Foster City, CA, USA) with the following PCR program:
95 ◦C for 5 min; 35 cycles at 95 ◦C for 30 s, at the specific annealing temperature for 30 s, at 72 ◦C
for 60 s; 72 ◦C for 5 min. Then, 10 µL of amplified PCR products were mixed with the loading dye,
containing Bromophenol Blue, and separated by electrophoresis on a 3% agarose gel. Bands were
displayed in an UV transilluminator. In all cases in which it was possible to discriminate different gel
bands, the different amplification products were purified using the Zyomoclean Gel DNA Recovery kit
(Zymo research, Irvine, CA-USA). In the remaining cases, unfractionated PCR products were purified
and cloned as previously described [33]. Each cDNA PCR products were sequenced using PE Big
dye terminator cycle sequencing kit on an ABI Prism 3130 Genetic Analyzer (Applied Biosystems).
The software Sequencer (v.4.9) was used for sequence analysis.
4.2.5. WT/Mutant Transcript Quantification by Quantitative Polymerase Chain Reaction (qPCR)
To quantify the relative expression levels of transcripts in mutant and control samples,
quantitative polymerase chain reaction (qPCR) with isoforms-specific primers (Supplementary Table S2)
was performed. A region not involved in splicing aberrations, and not subject to naturally occurring
alternative splicing [38,54], was selected as internal control to take into account the inter-individual
variability of BRCA1/2 expression. GUSB was used as housekeeping gene to normalize cDNA
amounts [42]. For controls the average value of ten samples was considered. Quantitative PCR was
carried out in single-plex reactions in a 96-well optical plate with FastStart SYBR Green Master Mix
(Roche) on the ABI Prism 7000 Sequence Detection System (Applied Biosystems). Experiments were
performed in triplicate in a final volume of 20 µL with 25 ng of cDNA and 25 nM of each primer,
following the SYBR Green protocol (Roche, Basel, Switzerland). Standard thermal cycling conditions
were: 2 min at 50 ◦C and 10 min at 95 ◦C; 40 cycles at 95 ◦C for 15 s and 60 ◦C for 1 min; dissociation
stage 95 ◦C for 15 s, 60 ◦C for 20 s and 95 ◦C for 15 s. The mean value of each triplicate was firstly
normalized to the housekeeping gene (∆Ct). The ∆Ct of the full-length and aberrant transcripts
was then normalized to that of the internal control (∆∆Ct), applying the comparative Ct method
to obtain the relative expression quantification [55]. In each sample, the expression levels of all
observed fragments were expressed as a percentage of the total expression of all fragments, i.e.,
analyzed transcript/(full-length + alternative transcripts).
4.2.6. Assessment of Partial/Total Effect on Splicing by the Use of Exonic Tag SNPs
Whenever possible informative exonic SNPs were analyzed to assess a total or partial effect
on splicing of investigated intronic variants. For each variant a PCR fragment spanning the exonic
tag-SNP was amplified from the canonical (full-length) transcript by the use of specific primers
(Supplementary Table S3) and sequenced to assess mono or biallelic expression.
4.2.7. In Vivo Splicing Assay with Minigenes
A portion of the gene containing the exon close to or harboring each variant of interest and part of
the flanking introns was amplified from patients’ genomic DNA (oligonucleotides and PCR conditions
are available upon request). PCR fragments were subsequently cloned into the β-globin-pCDNA3.1
vector to produce the hybrid minigene constructs, as previously described [56,57]. The mutant
minigene constructs, their corresponding wild-type versions or the empty vector were transfected
into HeLa cells and after 24 hours total RNA was extracted using the TRIzol kit (Invitrogen) and
reverse transcribed. The cDNA was then amplified using primers located on β-globin exons 2 and
3 and PCR fragments were separately sequenced as previously reported [57]. Puromycin treatment
of cell line transfected with the minigene carrying the BRCA1 c.302-5T > C variant was performed as
described [33].
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5. Conclusions
Our results provide further evidence of the usefulness of mRNA analysis for the clinical
classification of variants in disease-associated genes. In fact, through this approach we were able to
provide evidence assessing two BRCA2 variants (c.7618-2A>G and c.7806-2A>G) as pathogenic and
two BRCA1 variants (c.302-5T>C and c.441+5A>G) as benign. However, we also observed that a large
fraction (n = 6) of investigated spliceogenic variants retain the ability to produce (although at variable
levels) functional full-length transcripts, and therefore, cannot be definitively classified as pathogenic
according to current guidelines.
Due the availability of specific risk-reduction measures and new therapeutic approaches for
carriers of pathogenic BRCA gene variants, the development of ad hoc strategies for the classification
of variants with a partial splicing effect has become an urgent need. Along this line, two recent studies
of the ENIGMA consortium, combining genetic and clinical data analysis with accurate mRNA isoform
quantification, were able to demonstrate the non-pathogenicity of the BRCA1 c.[594-2A>C; 641A>G]
and BRCA2 c.68-7T>A leaky splicing variants [42,58]. In both cases, these investigations defined the
threshold for ratio between altered and functionally proficient gene transcripts not associated with
high cancer risk. These observations could inform the classification of other BRCA gene variants
causing partial spliceogenic effects, thus improving the informativeness of BRCA testing and the
number of families and individuals that can benefit from such tests.
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